We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of HCA (HCA) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that HCA Healthcare (HCA - Free Report) will report quarterly earnings of $5.01 per share in its upcoming release, pointing to a year-over-year increase of 1.6%. It is anticipated that revenues will amount to $16.84 billion, exhibiting an increase of 8% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some HCA metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Revenue per Equivalent Admission' should arrive at $17,449.01. Compared to the present estimate, the company reported $17,011 in the same quarter last year.
Analysts predict that the 'Equivalent Admissions' will reach 964.89 million. Compared to the current estimate, the company reported 916.54 million in the same quarter of the previous year.
The average prediction of analysts places 'Equivalent Patient Days' at 4,758.83 thousand. Compared to the current estimate, the company reported 4,603.14 thousand in the same quarter of the previous year.
Analysts' assessment points toward 'Number of hospitals' reaching 187. Compared to the current estimate, the company reported 180 in the same quarter of the previous year.
The consensus estimate for 'Licensed Beds at End of Period' stands at 49,285. Compared to the present estimate, the company reported 48,891 in the same quarter last year.
Analysts expect 'Same Facility - Equivalent Admissions' to come in at 949.98 thousand. The estimate is in contrast to the year-ago figure of 915.49 thousand.
The consensus among analysts is that 'Average Length of Stay' will reach 5. The estimate compares to the year-ago value of 5.
The combined assessment of analysts suggests that 'Number of freestanding outpatient surgery centers' will likely reach 124. The estimate is in contrast to the year-ago figure of 126.
It is projected by analysts that the 'Patient Days' will reach 2,708.50 Days. Compared to the present estimate, the company reported 2,637.9 Days in the same quarter last year.
According to the collective judgment of analysts, 'Admissions' should come in at 548.95 million. The estimate is in contrast to the year-ago figure of 525.24 million.
Over the past month, shares of HCA have returned -5.2% versus the Zacks S&P 500 composite's -4.2% change. Currently, HCA carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ahead of HCA (HCA) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Wall Street analysts forecast that HCA Healthcare (HCA - Free Report) will report quarterly earnings of $5.01 per share in its upcoming release, pointing to a year-over-year increase of 1.6%. It is anticipated that revenues will amount to $16.84 billion, exhibiting an increase of 8% compared to the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some HCA metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Revenue per Equivalent Admission' should arrive at $17,449.01. Compared to the present estimate, the company reported $17,011 in the same quarter last year.
Analysts predict that the 'Equivalent Admissions' will reach 964.89 million. Compared to the current estimate, the company reported 916.54 million in the same quarter of the previous year.
The average prediction of analysts places 'Equivalent Patient Days' at 4,758.83 thousand. Compared to the current estimate, the company reported 4,603.14 thousand in the same quarter of the previous year.
Analysts' assessment points toward 'Number of hospitals' reaching 187. Compared to the current estimate, the company reported 180 in the same quarter of the previous year.
The consensus estimate for 'Licensed Beds at End of Period' stands at 49,285. Compared to the present estimate, the company reported 48,891 in the same quarter last year.
Analysts expect 'Same Facility - Equivalent Admissions' to come in at 949.98 thousand. The estimate is in contrast to the year-ago figure of 915.49 thousand.
The consensus among analysts is that 'Average Length of Stay' will reach 5. The estimate compares to the year-ago value of 5.
The combined assessment of analysts suggests that 'Number of freestanding outpatient surgery centers' will likely reach 124. The estimate is in contrast to the year-ago figure of 126.
It is projected by analysts that the 'Patient Days' will reach 2,708.50 Days. Compared to the present estimate, the company reported 2,637.9 Days in the same quarter last year.
According to the collective judgment of analysts, 'Admissions' should come in at 548.95 million. The estimate is in contrast to the year-ago figure of 525.24 million.
View all Key Company Metrics for HCA here>>>
Over the past month, shares of HCA have returned -5.2% versus the Zacks S&P 500 composite's -4.2% change. Currently, HCA carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>